SynthesisDermatology and therapy2026
Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.
Synthesis in Dermatology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWhile rituximab has been approved for moderate-to-severe pemphigus vulgaris, data on pemphigus foliaceus (PF) remain limited because of the small number of patients included in therapeutic trials. However, current European guidelines recommend rituximab for the first-line treatment of patients with moderate-to-severe PF. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of rituximab in PF.
methodsThis systematic review and meta-analysis was conducted according to PRISMA guidelines and registered in PROSPERO (CRD42023428459). Studies published in English that included ≥ 3 patients with PF treated with rituximab were identified through six databases up to May 2025. Data on patient characteristics, rituximab regimens, clinical status at the end of follow-up, relapse rates, and severe adverse events (SAEs) were extracted.
resultsTwenty-four studies, published between 2012 and 2025, including 195 patients with PF, were analyzed. Mean age was 48.8 ± 20.8 years, and median follow-up was 24.5 months (interquartile range [IQR] 19-32.7). Rituximab was used as first-line therapy in 21% and as second-line therapy in 46.7% of patients (data not reported for 32.3% of patients), most frequently combined with oral corticosteroids (69.7%). The pooled complete remission (CR) rate was 75.0% (95% confidence interval (CI) 64.0-83.0; I
conclusionsRituximab appears to be a safe and effective treatment for PF. These findings support its use as first-line therapy in moderate-to-severe PF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.